Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Regorafenib (Primary)
- Indications Haemangiosarcoma
- Focus Therapeutic Use
- 09 Jan 2018 Planned End Date changed from 1 Nov 2019 to 1 Feb 2020.
- 30 Apr 2014 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University).
- 17 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.